(Q50571973)

15 March 2018

title

Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. (English)

1 reference

15 March 2018

1 reference

Ichiro Konishi

1

1 reference

15 March 2018

Norio Horiike

2

1 reference

15 March 2018

Yoichi Hiasa

3

1 reference

15 March 2018

Yoshio Tokumoto

4

1 reference

15 March 2018

Toshie Mashiba

5

1 reference

15 March 2018

Kojiro Michitaka

6

1 reference

15 March 2018

Yasuyuki Miyake

7

1 reference

15 March 2018

Suguru Nonaka

8

1 reference

15 March 2018

Kouji Joukou

9

1 reference

15 March 2018

Bunzo Matsuura

10

1 reference

15 March 2018

Morikazu Onji

11

1 reference

15 March 2018

publication date

1 May 2007

1 reference

15 March 2018

published in

Hepatology Research

1 reference

15 March 2018

volume

37

1 reference

15 March 2018

issue

5

1 reference

15 March 2018

page(s)

331-336

1 reference

15 March 2018

Hepatitis C virus infection is associated with the development of hepatocellular carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Relationship between the effect of interferon therapy and the change of hepatitis C virus non-structural 5B gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Association of mannose-binding lectin gene haplotype LXPA and LYPB with interferon-resistant hepatitis C virus infection in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

A single nucleotide polymorphism of the low molecular mass polypeptide 7 gene influences the interferon response in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

CCR5 promoter polymorphism influences the interferon response of patients with chronic hepatitis C in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Classification of chronic hepatitis: diagnosis, grading and staging

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Significance of serum hepatitis C virus RNA levels in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Association of diabetes mellitus and chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Glucose intolerance in Chinese patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Tumor necrosis factor alpha production by peripheral blood mononuclear cells of patients with chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Mechanisms of increased insulin resistance in non-cirrhotic patients with chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Serum concentration of gammaGT is a surrogate marker of hepatic TNF-alpha mRNA expression in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

What is disrupting IFN-alpha's antiviral activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Molecular understanding of hyperglycemia's adverse effects for diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1872-034X.2007.00052.X

10.1111/J.1872-034X.2007.00052.X

21 January 2018

Identifiers

DOI

1 reference

15 March 2018

1 reference

15 March 2018